Aripiprazole Monohydrate

Aripiprazole Monohydrate was approved by FDA (Abilify trade name) for the treatment of schizophrenia; manic and mixed episodes associated with bipolar I disorder; major depressive disorder; irritability associated with autistic disorder; Tourette's disorder and agitation associated with schizophrenia or bipolar mania. Reference standards of Aripiprazole Monohydrate API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

stdClass Object
(
    [pname] => Aripiprazole Monohydrate - API Standards 
    [catalogue_number] => PA 01 3380000
    [category_ids] => ,75,76,78,70,82,
    [chemical_name] => 
    [weight] => 466.4
    [form] => C23H29Cl2N3O3
    [cas] => 851220-85-4
    [pslug] => 851220-85-4-aripiprazole-monohydrate-api-pa013380000
    [latest_product] => 0
    [linkproducts] => 1
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)